Why the study?
Patients with systemic lupus erythematosus develop accelerated atherosclerosis and increased cardiovascular disease that traditional risk factors alone cannot explain.
Do HDL-targeted therapies reduce accelerated atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus?
Do HDL-targeted therapies reduce accelerated atherosclerosis and cardiovascular disease in patients with systemic lupus erythematosus?
Dysfunctional HDL may serve as a biomarker for accelerated atherosclerosis in SLE patients, highlighting HDL-targeted therapies as a potential intervention.
No takes yet. Share an insight, caveat, or question.
Dysfunctional HDL may mark higher CV risk in SLE; leaves open whether targeted therapies can mitigate atherosclerosis.
Kim et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: